Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 7/20 | 0.45 |
| ▸ | ACVRL1 | P37023 | 7/20 | 0.45 |
| ▸ | RET | P07949 | 4/20 | 0.45 |
| ▸ | ROS1 | P08922 | 4/20 | 0.45 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.45 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.45 |
| ▸ | MET | P08581 | 2/20 | 0.44 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.40 |
| ▸ | CCR2 | P41597 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | RHEB | Q15382 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL773434 | 0.95 | HTR4 (0.47) | NTRK1ACVRL1RETROS1NTRK3 | |
| SCHEMBL13692321 | 0.91 | NTRK1 (0.48) | NTRK1ACVRL1RETROS1NTRK3 | |
| Hydrochloric Acid SCHEMBL3466822 | 0.90 | NTRK1 (0.47) | NTRK1ACVRL1RETROS1NTRK3 | |
| SCHEMBL12136073 | 0.88 | NTRK1 (0.52) | NTRK1ACVRL1RETROS1NTRK3 | |
| SCHEMBL3459732 | 0.87 | NTRK1 (0.46) | NTRK1ACVRL1RETROS1NTRK3 | |
| SCHEMBL14734018 | 0.87 | NTRK1 (0.46) | NTRK1ACVRL1RETROS1NTRK3 | |
| SCHEMBL773873 | 0.86 | NTRK1 (0.44) | NTRK1ACVRL1RETROS1NTRK3 | |
| SCHEMBL10283983 | 0.85 | NTRK1 (0.46) | NTRK1ACVRL1RETROS1NTRK3 | |
| SCHEMBL16995320 | 0.85 | NTRK1 (0.44) | NTRK1ACVRL1RETROS1NTRK3 | |
| SCHEMBL774038 | 0.82 | NTRK1 (0.43) | NTRK1ACVRL1RETROS1NTRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9290503-B2 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION (US) | 2016-03-22 | — | — | US | disclosed |
| US-9249147-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2016-02-02 | — | — | US | disclosed |
| US-9249147-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2016-02-02 | — | — | US | disclosed |
| EP-2966076-A1 | NOVEL TYROSINE KINASE INHIBITORS | ChemBridge Corporation (US) | 2016-01-13 | — | — | EP | disclosed |
| EP-2966076-A1 | NOVEL TYROSINE KINASE INHIBITORS | ChemBridge Corporation (US) | 2016-01-13 | — | — | EP | disclosed |
| EP-2262807-B1 | NOVEL TYROSINE KINASE INHIBITORS | CHEMBRIDGE CORP (US) | 2015-08-12 | — | — | EP | disclosed |
| EP-2262807-B1 | NOVEL TYROSINE KINASE INHIBITORS | CHEMBRIDGE CORP (US) | 2015-08-12 | — | — | EP | disclosed |
| US-20150011539-A1 | NOVEL TYROSINE KINASE INHIBITORS | CHEMBRIDGE COPRPORATION | 2015-01-08 | — | — | US | disclosed |
| US-20150011539-A1 | NOVEL TYROSINE KINASE INHIBITORS | CHEMBRIDGE COPRPORATION | 2015-01-08 | — | — | US | disclosed |
| US-8815906-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815906-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2014-08-26 | — | — | US | disclosed |
| US-20140228350-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | CHEMBRIDGE CORPORATION (US) | 2014-08-14 | — | — | US | disclosed |
| US-20130053376-A1 | NOVEL TYROSINE KINASE INHIBITORS | CHEMBRIDGE COPRPORATION | 2013-02-28 | — | — | US | disclosed |
| US-20130053376-A1 | NOVEL TYROSINE KINASE INHIBITORS | CHEMBRIDGE COPRPORATION | 2013-02-28 | — | — | US | disclosed |
| EP-2262807-A1 | NOVEL TYROSINE KINASE INHIBITORS | ChemBridge Corporation (US) | 2010-12-22 | — | — | EP | disclosed |
| WO-2009117097-A1 | NOVEL TYROSINE KINASE INHIBITORS | CHEMBRIDGE CORPORATION (US) | 2009-09-24 | — | — | WO | disclosed |
| WO-2009117097-A1 | NOVEL TYROSINE KINASE INHIBITORS | CHEMBRIDGE CORPORATION (US) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228350-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | MALT1, TPMT, TSLP | NTRK1 718/4885ACVRL1 3502/4885RET 16/4885 |
| US-20150011539-A1 | NOVEL TYROSINE KINASE INHIBITORS | ABL1, RET, TTBK1 | NTRK1 331/4885ACVRL1 1949/4885RET 2/4885 |
| US-20130053376-A1 | NOVEL TYROSINE KINASE INHIBITORS | ABL1, RET, TTBK1 | NTRK1 331/4885ACVRL1 1949/4885RET 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.